Authors: Le Rolle, AF, Klempner, SJ, Garrett, CR, Seery, T, Sanford, EM, Balasubramanian, S, Ross, JS, Stephens, PJ, Miller, VA, Ali, SM, Chiu, VK

Source: Oncotarget
Le Rolle, AF; Klempner, SJ; Garrett, CR; Seery, T; Sanford, EM; Balasubramanian, S; et al.(2015). Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget, 6(30), 28929-28937. doi: 10.18632/oncotarget.4325. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/2749k799

Subject Terms: Research Paper, RET fusion kinase, RET kinase inhibitor, comprehensive genomic profiling, colorectal cancer, neoplasms, endocrine system diseases, endocrine system, congenital, hereditary, and neonatal diseases and abnormalities, digestive system diseases

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b6e4c83378fb8e958ca0b3eabf4ca6e1
http://europepmc.org/articles/PMC4745701

Authors: Klempner SJ, Cohen DW, Costa DB, Klempner, Samuel J, Cohen, David W, Costa, Daniel B

Source: Journal of Thoracic Oncology; 2011 Aug, Vol. 6 Issue 8, p1439-1440, 2p

Authors: Powderly JD; Cancer Research Clinic, Carolina BioOncology Institute, Huntersville, NC, USA., Klempner SJ; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bendell J; Drug Development Unit, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA., Garrido-Laguna I; Division of Oncology, University of Utah School of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA., Catenacci DVT; Department of Medicine, University of Chicago, Chicago, IL, USA., Taylor MH; Division of Hematology and Oncology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Lee JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburg, PA, USA., Zheng F; Incyte Corporation, Wilmington, DE, USA., Zhou F; Incyte Corporation, Wilmington, DE, USA., Gong X; Incyte Corporation, Wilmington, DE, USA., Gowda H; Incyte Corporation, Wilmington, DE, USA., Beatty GL; Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Source: The oncologist [Oncologist] 2022 Nov 03; Vol. 27 (11), pp. 905-e848.

Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Authors: Taylor MS, Connie W, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cheng WC, Heaps J, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Norden BL, Chait BT, Goggins M, Bhan I, Franses JW, Yang X, Taplin ME, Wang X, Christiani DC, Johnson BE, Meyerson M, Uppaluri R, Egloff AM, Denault EN, Spring LM, Wang TL, Shih IM, Jung E, Arora KS, Zukerberg LR, Yilmaz OH, Chi G, Matulonis UA, Song Y, Nieman L, Parikh AR, Strickland M, Corcoran RB, Mustelin T, Eng G, Yilmaz ÃH, Skates SJ, Rueda BR, Drapkin R, Klempner SJ, Deshpande V, Ting DT, Rout MP, LaCava J, Walt DR, Burns KH

Source: BioRxiv : the preprint server for biology [bioRxiv] 2023 Mar 17. Date of Electronic Publication: 2023 Mar 17.

Publication Type: Preprint

Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Authors: Sun Y; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Revach OY; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Anderson S; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kessler EA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Wolfe CH; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Jenney A; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA., Mills CE; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA., Robitschek EJ; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Davis TGR; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kim S; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Fu A; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ma X; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Gwee J; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Tiwari P; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Du PP; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sindurakar P; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Tian J; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Mehta A; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Schneider AM; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Yizhak K; Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Institute of Technology, Technion, Haifa, Israel., Sade-Feldman M; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., LaSalle T; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Sharova T; Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Xie H; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Liu S; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA., Michaud WA; Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Saad-Beretta R; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Yates KB; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Iracheta-Vellve A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Spetz JKE; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA.; Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, USA.; John B. Little Center for Radiation Sciences, Harvard School of Public Health, Boston, MA, USA., Qin X; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA.; Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, USA.; John B. Little Center for Radiation Sciences, Harvard School of Public Health, Boston, MA, USA., Sarosiek KA; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA.; Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, USA.; John B. Little Center for Radiation Sciences, Harvard School of Public Health, Boston, MA, USA., Zhang G; Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.; Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.; Preston Robert Tisch Brain Tumor Center, Department of Pathology, Duke University School of Medicine, Durham, NC, USA., Kim JW; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Center for Novel Therapeutics, UC San Diego, La Jolla, CA, USA.; Department of Medicine, UC San Diego, La Jolla, CA, USA., Su MY; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Cicerchia AM; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Rasmussen MQ; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Klempner SJ; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Juric D; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Pai SI; Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.; Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA., Miller DM; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Chen JH; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Pelka K; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Frederick DT; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Stinson S; Gilead Sciences, Foster City, CA, USA., Ivanova E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Aref AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Xsphera Biosciences, Boston, MA, USA., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Sen DR; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Fisher DE; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Corcoran RB; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Hacohen N; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sorger PK; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA., Flaherty KT; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Boland GM; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Manguso RT; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Jenkins RW; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. rjenkins@mgh.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. rjenkins@mgh.harvard.edu.; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA. rjenkins@mgh.harvard.edu.

Source: Nature [Nature] 2023 Mar; Vol. 615 (7950), pp. 158-167. Date of Electronic Publication: 2023 Jan 12.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

MeSH Terms: Immune Evasion*/genetics , Immune Evasion*/immunology , Immunotherapy*/methods , Protein Serine-Threonine Kinases*/antagonists & inhibitors , Protein Serine-Threonine Kinases*/genetics , Drug Resistance, Neoplasm*, Humans ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Organoids ; Tumor Necrosis Factors/immunology ; Interferon-gamma/immunology ; Spheroids, Cellular ; Caspases ; Janus Kinases ; STAT Transcription Factors

Authors: Klempner SJ; Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, USA. Electronic address: sklempner@partners.org., Janjigian YY; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA., Wainberg ZA; Department of Medicine, Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, USA.

Source: ESMO open [ESMO Open] 2023 Feb 13; Vol. 8 (2), pp. 100778. Date of Electronic Publication: 2023 Feb 13.

Publication Type: Editorial

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Authors: Tian J; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Chen JH; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Chao SX; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Pelka K; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.; Gladstone-UCSF Institute of Genomic Immunology, Gladstone Institutes Department of Microbiology and Immunology, UCSF, San Francisco, CA, USA., Giannakis M; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Hess J; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Burke K; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Jorgji V; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Sindurakar P; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Braverman J; The Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA., Mehta A; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Oka T; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Huang M; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Lieb D; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Spurrell M; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Allen JN; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Abrams TA; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Clark JW; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Enzinger AC; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Enzinger PC; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Klempner SJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., McCleary NJ; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Meyerhardt JA; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Ryan DP; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Yurgelun MB; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Kanter K; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Van Seventer EE; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Baiev I; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Chi G; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Jarnagin J; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Bradford WB; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Wong E; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Michel AG; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Fetter IJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Siravegna G; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Gemma AJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Sharpe A; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA., Demehri S; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Leary R; Novartis Institute for Biomedical Research, Cambridge, MA, USA., Campbell CD; Novartis Institute for Biomedical Research, Cambridge, MA, USA., Yilmaz O; The Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA., Getz GA; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Parikh AR; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Hacohen N; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. NHACOHEN@mgh.harvard.edu.; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA. NHACOHEN@mgh.harvard.edu., Corcoran RB; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. rbcorcoran@partners.org.

Source: Nature medicine [Nat Med] 2023 Feb; Vol. 29 (2), pp. 458-466. Date of Electronic Publication: 2023 Jan 26.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

MeSH Terms: Melanoma*/pathology , Colorectal Neoplasms*/genetics, Humans ; Proto-Oncogene Proteins B-raf/genetics ; Programmed Cell Death 1 Receptor/genetics ; Mitogen-Activated Protein Kinase Kinases/genetics ; Mutation ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Pyridones/therapeutic use ; Pyrimidinones/therapeutic use ; Protein Kinase Inhibitors/pharmacology

Authors: Yaeger R; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Weiss J; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Pelster MS; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Spira AI; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Barve M; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Ou SI; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Leal TA; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Bekaii-Saab TS; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Paweletz CP; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Heavey GA; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Christensen JG; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Velastegui K; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Kheoh T; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Der-Torossian H; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston., Klempner SJ; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research Institute, Tennessee Oncology, Nashville (M.S.P.); Virginia Cancer Specialists, NEXT Oncology-Virginia, Fairfax (A.I.S.); US Oncology Research, the Woodlands (A.I.S.), and Mary Crowley Cancer Research, Dallas (M.B.) - both in Texas; the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), and Mirati Therapeutics, San Diego (J.G.C., K.V., T.K., H.D.-T.) - all in California; the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta (T.A.L.); Medical Oncology, Mayo Clinic, Phoenix, Arizona (T.S.B.-S.); Belfer Center for Applied Cancer Science and the Department of Medical Oncology, Dana-Farber Cancer Institute (C.P.P., G.A.H.), and the Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital (S.J.K.) - both in Boston.

Source: The New England journal of medicine [N Engl J Med] 2023 Jan 05; Vol. 388 (1), pp. 44-54. Date of Electronic Publication: 2022 Dec 21.

Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

MeSH Terms: Cetuximab*/administration & dosage , Cetuximab*/adverse effects , Cetuximab*/therapeutic use , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/secondary , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/therapeutic use, Humans ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Piperazines/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics

Authors: Quintanilha JCF; Foundation Medicine, Cambridge, Massachusetts., Graf RP; Foundation Medicine, Cambridge, Massachusetts., Fisher VA; Foundation Medicine, Cambridge, Massachusetts., Oxnard GR; Foundation Medicine, Cambridge, Massachusetts., Ellis H; Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston., Panarelli N; Medicine/Gastroenterology, Montefiore Medical Center, Albert Einstein Cancer Center, New York, New York., Lin DI; Foundation Medicine, Cambridge, Massachusetts., Li G; Foundation Medicine, Cambridge, Massachusetts., Huang RSP; Foundation Medicine, Cambridge, Massachusetts., Ross JS; Foundation Medicine, Cambridge, Massachusetts.; SUNY Upstate Medical University, Syracuse, New York., Myer PA; Medicine/Gastroenterology, Montefiore Medical Center, Albert Einstein Cancer Center, New York, New York., Klempner SJ; Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston.

Source: JAMA network open [JAMA Netw Open] 2023 Jan 03; Vol. 6 (1), pp. e2252244. Date of Electronic Publication: 2023 Jan 03.

Publication Type: Journal Article

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

MeSH Terms: Colonic Neoplasms*/drug therapy , Colorectal Neoplasms* , Rectal Neoplasms*/drug therapy, Aged ; Female ; Humans ; Male ; Middle Aged ; Biomarkers, Tumor ; DNA Mismatch Repair ; Immune Checkpoint Inhibitors/therapeutic use ; Microsatellite Instability ; Comparative Effectiveness Research

SCR Disease Name: Turcot syndrome

Authors: Kim DW; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA., Lee G; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA., Li G; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Horick NK; Massachusetts General Hospital Biostatistics Center, Boston, MA, USA., Roeland E; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Keane FK; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA., Eyler C; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA., Drapek LC; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA., Ryan DP; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Allen JN; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Berger D; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA., Parikh AR; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Mullen JT; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA., Klempner SJ; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Clark JW; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Wo JY; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. jwo@mgh.harvard.edu.

Source: Annals of surgical oncology [Ann Surg Oncol] 2022 Jan; Vol. 29 (1), pp. 242-252. Date of Electronic Publication: 2021 Sep 03.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE

Authors: Hachey SJ; Irvine Department of Molecular Biology and Biochemistry, University of California, Irvine, California., Sobrino A; Irvine Department of Molecular Biology and Biochemistry, University of California, Irvine, California., Lee JG; Irvine School of Medicine, University of California, Irvine, California., Jafari MD; Department of Surgery, Weill Cornell Medicine, New York, New York., Klempner SJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Puttock EJ; Irvine Department of Mathematics, University of California, Irvine, California., Edwards RA; Irvine School of Medicine, University of California, Irvine, California., Lowengrub JS; Irvine Department of Mathematics, University of California, Irvine, California., Waterman ML; Irvine Department of Microbiology and Molecular Genetics, University of California, Irvine, California., Zell JA; Irvine School of Medicine, University of California, Irvine, California., Hughes CCW; Irvine Department of Molecular Biology and Biochemistry, University of California, Irvine, California; Irvine Department of Biomedical Engineering, University of California, Irvine, California. Electronic address: cchughes@uci.edu.

Source: Translational research : the journal of laboratory and clinical medicine [Transl Res] 2022 Dec 05. Date of Electronic Publication: 2022 Dec 05.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101280339 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1810 (Electronic) Linking ISSN: 18781810 NLM ISO Abbreviation: Transl Res Subsets: MEDLINE

Authors: Huffman BM; Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA., Aushev VN; Natera, Inc, Austin, TX., Budde GL; Natera, Inc, Austin, TX., Chao J; City of Hope Comprehensive Cancer Center, Duarte, CA., Dayyani F; University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA., Hanna D; Keck Hospital of USC, Los Angeles, CA., Botta GP; UCSD Moores Cancer Center, La Jolla, CA., Catenacci DVT; University of Chicago, Chicago, IL., Maron SB; Memorial Sloan Kettering Cancer Center, New York City, NY., Krinshpun S; Natera, Inc, Austin, TX., Sharma S; Natera, Inc, Austin, TX., George GV; Natera, Inc, Austin, TX., Malhotra M; Natera, Inc, Austin, TX., Jurdi A; Natera, Inc, Austin, TX., Moshkevich S; Natera, Inc, Austin, TX., Aleshin A; Natera, Inc, Austin, TX., Kasi PM; Weill Cornell Medicine, Englander Institute of Precision Medicine, New York Presbyterian Hospital, New York, NY., Klempner SJ; Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA.

Source: JCO precision oncology [JCO Precis Oncol] 2022 Dec; Vol. 6, pp. e2200420.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

MeSH Terms: Circulating Tumor DNA*/genetics , Stomach Neoplasms*/genetics , Esophageal Neoplasms*/genetics, Humans ; Retrospective Studies

Authors: Staller KD; From the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Massachusetts General Hospital, and the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Harvard Medical School - both in Boston., Badran YR; From the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Massachusetts General Hospital, and the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Harvard Medical School - both in Boston., Rosman DA; From the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Massachusetts General Hospital, and the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Harvard Medical School - both in Boston., Klempner SJ; From the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Massachusetts General Hospital, and the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Harvard Medical School - both in Boston., Judelson R; From the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Massachusetts General Hospital, and the Departments of Medicine (K.D.S., Y.R.B., S.J.K.), Radiology (D.A.R.), and Pathology (R.J.), Harvard Medical School - both in Boston.

Source: The New England journal of medicine [N Engl J Med] 2022 Oct 13; Vol. 387 (15), pp. 1415-1424.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

MeSH Terms: Heartburn*/etiology , Nausea*/etiology , Anorexia*/etiology, Aged ; Humans ; Male ; Vomiting/etiology

Authors: Catenacci DVT; Department of Medicine, The University of Chicago Medical Centre, Chicago, USA. Electronic address: DocCatenacci@catenacciconsulting.com., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Yoon HH; Division of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, USA., Shim BY; Medical Oncology, The Catholic University of Korea St. Vincent's Hospital, Suwon, Republic of Korea., Kim ST; Hematology and Oncology, Samsung Medical Center, Seoul, Republic of Korea., Oh DY; Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea., Spira AI; Virginia Cancer Specialists Research Institute, Fairfax, USA., Ulahannan SV; University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, USA., Avery EJ; Division of Hematology and Oncology, Nebraska Hematology-Oncology, Lincoln, USA., Boland PM; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA., Chao J; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA., Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Gardner F; Medical Oncology, Florida Cancer Specialists, Cape Coral, USA., Klempner SJ; Mass General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA., Lee KW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam., Oh SC; Oncology, Korea University Guro Hospital, Seoul, Republic of Korea., Peguero J; Medical Oncology, Oncology Consultants, Houston, USA., Sonbol MB; Internal Medicine Department, Mayo Clinic Cancer Center, Phoenix, USA., Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China., Moehler M; Johannes-Gutenberg University, Mainz, Germany., Sun J; MacroGenics, Inc., Rockville, USA., Li D; MacroGenics, Inc., Rockville, USA., Rosales MK; MacroGenics, Inc., Rockville, USA., Park H; Department of Medicine, Washington University School of Medicine, St. Louis, USA.

Source: ESMO open [ESMO Open] 2022 Oct; Vol. 7 (5), pp. 100563. Date of Electronic Publication: 2022 Aug 24.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

MeSH Terms: Adenocarcinoma*/drug therapy , Adenocarcinoma*/pathology , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/pathology, Humans ; B7-H1 Antigen/metabolism ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Immune Checkpoint Inhibitors

Authors: Catenacci DV; University of Chicago Medical Center & Biological Sciences, Chicago, Illinois, USA., Chao J; City of Hope Comprehensive Cancer Center, Duarte, California, USA., Muro K; Aichi Cancer Center Hospital, Nagoya, Japan., Al-Batran SE; Institute of Clinical Cancer Research Krankenhaus Nordwest, Frankfurt, Germany., Klempner SJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Wainberg ZA; UCLA Santa Monica Medical Center, Santa Monica, California, USA., Shah MA; Weill Cornell Medicine, New York, New York, USA., Rha SY; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Ohtsu A; National Cancer Center Hospital East, Chiba, Japan., Liepa AM; Eli Lilly & Co, Indianapolis, Indiana, USA., Knoderer H; Eli Lilly & Co, Indianapolis, Indiana, USA., Chatterjee A; Eli Lilly & Co, Indianapolis, Indiana, USA., Van Cutsem E; Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.

Source: The oncologist [Oncologist] 2021 Oct; Vol. 26 (10), pp. e1704-e1729. Date of Electronic Publication: 2021 Sep 03.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Systematic Review

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Authors: Mansoor W; The Christie NHS Foundation Trust, Manchester, United Kingdom., Roeland EJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Chaudhry A; Eli Lilly and Company, Indianapolis, Indiana, USA., Liepa AM; Eli Lilly and Company, Indianapolis, Indiana, USA., Wei R; Eli Lilly and Company, Indianapolis, Indiana, USA., Knoderer H; Eli Lilly and Company, Indianapolis, Indiana, USA., Abada P; Eli Lilly and Company, Indianapolis, Indiana, USA., Chatterjee A; Eli Lilly and Company, Indianapolis, Indiana, USA., Klempner SJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

Source: The oncologist [Oncologist] 2021 Sep; Vol. 26 (9), pp. e1538-e1547. Date of Electronic Publication: 2021 Jun 09.

Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Authors: Dowlati A; Department of Medicine Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA., Harvey RD; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Carvajal RD; Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons New York, New York, NY, USA., Hamid O; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Cedars-Sinai Affiliate, Los Angeles, CA, USA., Klempner SJ; Department of Medicine and Oncology, Massachusetts General Hospital, Boston, MA, USA., Kauh JSW; Medical Oncology, Hutchison MediPharma Inc., Florham Park, NJ, USA., Peterson DA; Eli Lilly and Company, Indianapolis, IN, USA., Yu D; Eli Lilly and Company, Indianapolis, IN, USA., Chapman SC; Eli Lilly and Company, Windlesham, Surrey, UK., Szpurka AM; Eli Lilly and Company, Indianapolis, IN, USA., Carlsen M; Eli Lilly and Company, Indianapolis, IN, USA., Quinlan T; Eli Lilly and Company, Indianapolis, IN, USA., Wesolowski R; Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1310D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Robert.Wesolowski@osumc.edu.

Source: Investigational new drugs [Invest New Drugs] 2021 Aug; Vol. 39 (4), pp. 1057-1071. Date of Electronic Publication: 2021 Feb 23.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Authors: Loaiza-Bonilla A; Department of Medical Oncology, Cancer Treatment Centers of America, Philadelphia, Pennsylvania, USA., Benson AB 3rd; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Grothey A; West Cancer Center, Germantown, Tennessee, USA., Karimi M; Department of Medical Oncology & Therapeutics Research, City of Hope, Newport Beach, California, USA., Klempner SJ; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Lin D; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA., Mahtani R; University of Miami, Miami, Florida, USA., Soares HP; Huntsman Cancer Center at University of Utah, Salt Lake City, Utah, USA.

Source: The oncologist [Oncologist] 2021 Aug; Vol. 26 (8), pp. 651-659. Date of Electronic Publication: 2021 Mar 28.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Authors: Graf RP; Foundation Medicine, Cambridge, Massachusetts., Fisher V; Foundation Medicine, Cambridge, Massachusetts., Creeden J; Foundation Medicine, Cambridge, Massachusetts., Schrock AB; Foundation Medicine, Cambridge, Massachusetts., Ross JS; Foundation Medicine, Cambridge, Massachusetts.; Upstate Medical University, Syracuse, New York., Nimeiri H; Foundation Medicine, Cambridge, Massachusetts., Oxnard GR; Foundation Medicine, Cambridge, Massachusetts., Klempner SJ; Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts.

Source: Cancer research communications [Cancer Res Commun] 2022 Sep 21; Vol. 2 (9), pp. 1037-1048. Date of Electronic Publication: 2022 Sep 21 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: PubMed not MEDLINE

Authors: Maron SB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, New York, NY., Moya S; Department of Medicine, Division of Hematology-Oncology, University of Chicago School of Medicine, Chicago, IL., Morano F; Oncologia Medica, Instituto Nazionale dei Tumori di Milano, Milan, Italy., Emmett MJ; Massachusetts General Hospital, Boston, MA., Chou JF; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Sabwa S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Walch H; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.; Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY., Peterson B; Department of Medicine, Division of Hematology-Oncology, University of Chicago School of Medicine, Chicago, IL., Schrock AB; Foundation Medicine, Inc, Cambridge, MA., Zhang L; Foundation Medicine, Inc, Cambridge, MA., Janjigian YY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, New York, NY., Chalasani S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Ku GY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, New York, NY., Disel U; Department of Medical Oncology, Adana Acibadem Hospital, Adana, Turkey., Enzinger P; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA., Uboha N; Department of Medicine, Section of Hematology & Oncology, Carbone Cancer Center, University of Wisconsin, Madison, WI., Kato S; Department of Medicine, University of California San Diego Moores Cancer Center, La Jolla, CA., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Nakamura Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Saeed A; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS., Kasi PM; Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Medicine, University of Iowa, Iowa City, IA., Chao J; Department of Developmental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA., Lee J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Capanu M; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Wainberg Z; Division of Oncology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA., Petty R; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Pietrantonio F; Oncologia Medica, Instituto Nazionale dei Tumori di Milano, Milan, Italy., Klempner SJ; Massachusetts General Hospital, Boston, MA., Catenacci DVT; Department of Medicine, Division of Hematology-Oncology, University of Chicago School of Medicine, Chicago, IL.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Aug 01; Vol. 40 (22), pp. 2458-2467. Date of Electronic Publication: 2022 Mar 29.

Publication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

MeSH Terms: Adenocarcinoma*/drug therapy , Adenocarcinoma*/genetics , Adenocarcinoma*/pathology , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/genetics , Esophageal Neoplasms*/pathology , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Stomach Neoplasms*/pathology, Antibodies, Bispecific ; ErbB Receptors ; Humans ; In Situ Hybridization, Fluorescence ; Retrospective Studies